Top Markets
#1 Black Phoenix Black Phoenix +355.71%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +57.01%
#4 Gold Park Gold Park +55.15%
#5 Acurast Acurast +28.90%
#6 BasedHype BasedHype +28.38%
#7 Cryptopia Cryptopia +22.67%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.42%
#9 Avantis Avantis +16.65%
#10 HOME HOME +15.01%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Neuropathix, Inc. Neuropathix, Inc.

Neuropathix, Inc.

NPTX
Rank in Stocks #41303
Neuropathix, Inc. is a biopharmaceutical firm dedicated to identifying,... Neuropathix, Inc. is a biopharmaceutical firm dedicated to identifying, advancing, and bringing to market innovative treatments derived from its exclusive platform of synthetic cannabinoid derivatives. The company's efforts are concentrated on the research and preclinical development of chemical compounds like KLS-13019, KLS-13023, and KLS-13022, alongside associated molecules and synthetic cannabidiol-based therapies. These investigational drugs are being explored for their potential application in treating various conditions, including chemotherapy-induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. Previously operating as Kannalife, Inc., the organization rebranded as Neuropathix, Inc. in November 2020. Established in 2010, Neuropathix, Inc. maintains its headquarters in Doylestown, Pennsylvania.
Share Price
$0.0003
Last synced: 2023-06-13
Market Cap
$28.14K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Neuropathix, Inc. (NPTX)

Category

Healthcare
P/E ratio for Neuropathix, Inc. (NPTX)
P/E ratio as of 2026 TTM: 0
According to Neuropathix, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Neuropathix, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.